Such effects are consistent with their established reduction in atherosclerotic cardiovascular events and may be particularly relevant in patients with obesity, insulin resistance, or HFpEF phenotypes, and taken together, these mechanistic differences provide a biologically plausible rationale for combination therapy: SGLT2 inhibitors primarily target HF-related hemodynamic and cardiorenal pathways, whereas GLP-1 receptor agonists may further improve metabolic and vascular risk
In one study, among patients with non-small cell lung cancer treated with anti-PD-1/PD-L1, those who received corticosteroids to manage their irAE had reduced clinical benefit from immunotherapy, with shorter progression-free survival and overall survival
In a recent meta-analysis, 40 out of 44 studies (90.9%) showed a tumor inhibitory effect of CR in laboratory animals with respect to tumor incidence, progression or metastasis
Drinking alcohol, is like adding an accelerator to the crash
Monitor your body for signs of nutrient gaps: extreme fatigue, hair loss, or dizziness months into treatment may signal insufficient protein, iron, or B vitamins
.jpeg)
